An overview of the British Columbia Glomerulonephritis network and registry: integrating knowledge generation and translation within a single framework

BMC Nephrology

Adeera Levin²  Heather Reich³  Ognjenka Djurdjev¹  Jagbir Gill²  Monica Beaulieu¹  Sean Barbour² 

[1] BC Provincial Renal Agency, Vancouver, BC, Canada;Centre for Health Evaluation and Outcomes Research, St. Paul’s Hospital, Vancouver, BC, Canada;Division of Nephrology, University of Toronto, Toronto, BC, Canada

关键词: Canada;    British Columbia;    Knowledge translation;    Health services;    Database;    Registry;    Glomerulonephritis;   

Others  :  1082803
DOI  :  10.1186/1471-2369-14-236

 received in 2013-08-14, accepted in 2013-10-24,  发布年份 2013

【 摘 要 】

Background

Glomerulonephritis (GN) is a group of rare kidney diseases with a substantial health burden and high risk of progression to end-stage renal disease. Research in GN has been limited by poor availability of large comprehensive registries. Substantial variations in access to and administration of treatment and outcomes in GN have been described. Leveraging provincial resources and existing infrastructure, the British Columbia (BC) GN Network is an initiative which serves to combine research and clinical care objectives. The goal of the BC GN Network is to coordinate and improve health care, including robust data capture, on all patients with GN in BC, a Canadian province of over 4.6 million people. This provincial initiative will serve as a model for Canadian or other national and international endeavours.

Description

The BC Provincial Renal Agency (BCPRA) is the provincial governmental agency responsible for health delivery for all kidney patients in BC. The BC GN Network has been created by the BCPRA to ensure high quality and equitable access to care for all patients with GN and is a platform for evidence based clinical care programs and associated health policy. All patients with biopsy-proven GN are registered at the time of kidney biopsy into the BCPRA provincial database of kidney disease patients, forming the BC GN Registry. Thereafter, all laboratory results and renal related outcomes are captured automatically. Histology data and core clinical variables are entered into the database. Additional linkages between the GN Registry and administrative databases ensure robust capture of medications, hospital admissions, health care utilization, comorbidities, cancer and cardiac outcomes, and vital statistics.

Conclusions

The BC GN Network and Registry is a unique model in that it combines robust data capture, data linkages, and health care delivery and evaluation into one integrated system. This model utilizes existing health infrastructure to prospectively capture population level data on patients with GN, producing a rich dataset capable of real-time identification and evaluation of GN health policy initiatives, of supporting observational cohort studies and health services research in GN, and of facilitating patient recruitment into GN clinical trials.

【 授权许可】

   
2013 Barbour et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 2.

【 参考文献 】

• [1]Leaf DE, Appel GB, Radhakrishnan J: Glomerular disease: why is there a dearth of high quality clinical trials? Kidney Int 2010, 78(4):337-342.
• [2]McGrogan A, Franssen CF, de Vries CS: The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant 2011, 26(2):414-30.
• [3]Canadian Institute for Health Information: Annual Report—Treatment of End-Stage Organ Failure in Canada, 2001 to 2010. 2012. https://secure.cihi.ca/estore/productFamily.htm?locale=en&pf=PFC1696 webcite
• [4]Chou YH, Lien YC, Hu FC, Lin WC, Kao CC, Lai CF, et al.: Clinical Outcomes and Predictors for ESRD and Mortality in Primary GN. Clin J Am Soc Nephrol 2012, 7(9):1401-8.
• [5]Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC: Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int 2004, 66(3):1199-205.
• [6]Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC: Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol 2005, 16(4):1061-8.
• [7]Schieppati A, Mosconi L, Perna A, Mecca G, Bertani T, Garattini S, et al.: Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 1993, 329(2):85-9.
• [8]Reich HN, Troyanov S, Scholey JW, Cattran DC: Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 2007, 18(12):3177-83.
• [9]Cattran DC, Rao P: Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 1998, 32(1):72-9.
• [10]Pesce F, Schena FP: Worldwide distribution of glomerular diseases: the role of renal biopsy registries. Nephrol Dial Transplant 2010, 25(2):334-6.
• [11]Barbour S, Er L, Magil A, Reich H, Levin A: Ethnic differences in renal and patient survival in IgA nephropathy. Abstract at the World Congress of Nephrology; 2011.
• [12]Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, et al.: The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009, 76(5):534-45.
• [13]Komenda P, Beaulieu M, Seccombe D, Levin A: Regional implementation of creatinine measurement standardization. J Am Soc Nephrol 2008, 19(1):164-9.
• [14]Curtis BM, Ravani P, Malberti F, Kennett F, Taylor PA, Djurdjev O, et al.: The short- and long-term impact of multi-disciplinary clinics in addition to standard nephrology care on patient outcomes. Nephrol Dial Transplant 2005, 20(1):147-54.
• [15]Weber C, Beaulieu M, Djurdjev O, Er L, Taylor P, Ignaszewski A, et al.: Towards rational approaches of health care utilization in complex patients: an exploratory randomized trial comparing a novel combined clinic to multiple specialty clinics in patients with renal disease-cardiovascular disease-diabetes. Nephrol Dial Transplant 2012, 27(3):iii104-110.
• [16]Beaulieu M, Krajden M, Buxton J, Er L, Djurdjev O, Levin A: Variability of hepatitis B testing in British Columbian ESRD patients: the case to focus on implementation of guidelines. Am J Kidney Dis 2008, 52(5):939-46.
• [17]Kiaii M, Djurdjev O, Farah M, Levin A, Jung B, MacRae J: Use of electron-beam sterilized hemodialysis membranes and risk of thrombocytopenia. JAMA 2011, 306(15):1679-87.
• [18]Regional program for the study of glomerulonephritis: Central Committee of the Toronto Glomerulonephritis Registry. Can Med Assoc J 1981, 124(2):158-61.
• [19]Schena FP, Cerullo G, Torres DD, Scolari F, Foramitti M, Amoroso A, et al.: The IgA nephropathy Biobank. An important starting point for the genetic dissection of a complex trait. BMC Nephrol 2005, 6:14. BioMed Central Full Text
• [20]Rivera F, Lopez-Gomez JM, Perez-Garcia R: Clinicopathologic correlations of renal pathology in Spain. Kidney Int 2004, 66(3):898-904.
• [21]Rivera F, Lopez-Gomez JM, Perez-Garcia R: Frequency of renal pathology in Spain 1994–1999. Nephrol Dial Transplant 2002, 17(9):1594-602.
• [22]Li LS, Liu ZH: Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. Kidney Int 2004, 66(3):920-3.
• [23]KDIGO Clinical Practice Guidelines for Glomerulonephritis Kidney Int 2012, S2(2):139-274.
• [24]Fuiano G, Mazza G, Comi N, Caglioti A, De Nicola L, Iodice C, et al.: Current indications for renal biopsy: a questionnaire-based survey. Am J Kidney Dis 2000, 35(3):448-57.